Danaher Corporation (DHR)
Danaher Corporation (DHR) is a global science and technology innovator that designs, manufactures, and markets professional, medical, industrial, and consumer products and services. Founded in 1984, the company operates through various segments, including life sciences, diagnostics, and environmental & applied solutions, serving customers in health, environmental, and industrial markets worldwide. Danaher is known for its focus on continuous improvement and leveraging science and technology to solve complex problems.
Dividend History
Investors can expect a dividend payout of $0.32 per share, scheduled to be distributed in 41 days on October 31, 2025
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| October 31, 2025 | $0.32 | 2025-09-26 | 2025-09-26 |
| July 25, 2025 | $0.32 | 2025-06-27 | 2025-06-27 |
| April 25, 2025 | $0.32 | 2025-03-28 | 2025-03-28 |
| January 31, 2025 | $0.27 | 2024-12-27 | 2024-12-27 |
| October 25, 2024 | $0.27 | 2024-09-27 | 2024-09-27 |
Dividends Summary
- Danaher Corporation has issued 88 dividend payments over the past 21 years
- The most recent dividend was paid 57 days ago, on July 25, 2025
- The highest dividend payed out to investors during this period was $0.32 per share
- The average dividend paid during this period was $0.11 per share.
Company News
Rosen Law Firm is investigating potential breaches of fiduciary duties by directors and officers of Danaher Corporation, encouraging shareholders to contact them for more information.
Danaher Corporation has declared a quarterly cash dividend of $0.32 per share, payable on October 31, 2025, to shareholders of record as of September 26, 2025.
Danaher reported strong Q2 2025 results with $5.9 billion in sales, 1.5% core revenue growth, and raised full-year EPS guidance. Bioprocessing segment showed resilience with low double-digit consumables growth and strategic mitigation of tariff challenges.
Three companies (Thor Industries, Fair Isaac, and Danaher) are enhancing shareholder value through strategic buybacks, debt reduction, and dividend programs, signaling potential undervaluation and financial optimization.
The article discusses the latest research reports on Danaher, Morgan Stanley, Pfizer, Elite Pharmaceuticals, and Oil-Dri. It highlights the key strengths and challenges faced by these companies.
